Skip to content

Study · Animal study (in vivo) · hamster · 2004

7 results

Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters.

Iwase M, Kanazawa H, Kato Y, Nishizawa T, Somura F, Ishiki R, Nagata K, Hashimoto K, Takagi K, Izawa H, Yokota M

Cardiovascular research1 Jan 2004Cited by 25 (Europe PMC)

PMID14732199 (opens in a new tab)DOI10.1016/j.cardiores.2003.10.012 (opens in a new tab)PepBankPUB-14732199
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In TO-2 hamsters, body weight gain was lower with GHRP‑6 than with GH.

    In plain wordsIn hamsters with cardiomyopathy, GHRP‑6 produced less weight gain than GH.

    Peptide
    GHRP-6
    Outcome
    DecreaseBody weight gain versus GH
    Study

    hamstern: not reported in source

    TO-2 dilated cardiomyopathy
    Comparator
    GH
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    100 microg/kg day · injection · 4 weeksAs given in this study (hamster).

    Source sentences

    Summary
    The increase in body weight of GH-treated TO-2 hamsters was greater than that of animals in the other two groups.
    2 context sentences
    Summary · context
    TO-2 hamsters (8 weeks old) were injected with GHRP-6 (100 microg/kg day), GH (2 mg/kg day), or saline for 4 weeks; F1B hamsters served as controls.
    Summary · context
    LV functional and structural changes were evaluated by echocardiography and pathology.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In TO-2 hamsters, GHRP‑6 did not increase plasma GH concentrations.

    In plain wordsIn hamsters with cardiomyopathy, GHRP‑6 did not increase blood growth hormone levels compared with saline.

    Peptide
    GHRP-6
    Outcome
    No significant changePlasma GH
    Study

    hamstern: not reported in source

    TO-2 dilated cardiomyopathy
    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microg/kg day · injection · 4 weeksAs given in this study (hamster).

    Source sentences

    Summary
    Plasma GH and insulin-like growth factor-1 (IGF-1) concentrations were not increased by GHRP-6.
    2 context sentences
    Summary · context
    TO-2 hamsters (8 weeks old) were injected with GHRP-6 (100 microg/kg day), GH (2 mg/kg day), or saline for 4 weeks; F1B hamsters served as controls.
    Summary · context
    LV functional and structural changes were evaluated by echocardiography and pathology.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In TO-2 hamsters, GHRP‑6 did not increase plasma IGF-1 concentrations.

    In plain wordsIn hamsters with cardiomyopathy, GHRP‑6 did not increase blood IGF-1 levels compared with saline.

    Peptide
    GHRP-6
    Outcome
    No significant changePlasma IGF-1
    Study

    hamstern: not reported in source

    TO-2 dilated cardiomyopathy
    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microg/kg day · injection · 4 weeksAs given in this study (hamster).

    Source sentences

    Summary
    Plasma GH and insulin-like growth factor-1 (IGF-1) concentrations were not increased by GHRP-6.
    2 context sentences
    Summary · context
    TO-2 hamsters (8 weeks old) were injected with GHRP-6 (100 microg/kg day), GH (2 mg/kg day), or saline for 4 weeks; F1B hamsters served as controls.
    Summary · context
    LV functional and structural changes were evaluated by echocardiography and pathology.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In TO-2 hamsters, GHRP‑6 improved LV fractional shortening compared with untreated animals.

    In plain wordsIn hamsters with cardiomyopathy, GHRP‑6 improved heart contraction compared with untreated animals.

    Peptide
    GHRP-6
    Outcome
    IncreaseLV fractional shortening
    Study

    hamstern: not reported in source

    TO-2 dilated cardiomyopathy
    Comparator
    Saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    100 microg/kg day · injection · 4 weeksAs given in this study (hamster).

    Measurements

    LV fractional shortening
    33.4%
    GHRP-6

    Source sentences

    Summary
    LVFS was substantially improved by treatment with GHRP-6 (33.4+/-2.0%) or GH (32.0+/-2.1%).
    3 context sentences
    Summary · context
    LV fractional shortening (LVFS) decreased from 42.0+/-2.6% to 25.4+/-1.8% and the LV end-diastolic dimension (LVDd) increased from 4.0+/-0.1 to 5.0+/-0.1 mm in untreated TO-2 hamsters between 8 and 12 weeks.
    Summary · context
    TO-2 hamsters (8 weeks old) were injected with GHRP-6 (100 microg/kg day), GH (2 mg/kg day), or saline for 4 weeks; F1B hamsters served as controls.
    Summary · context
    LV functional and structural changes were evaluated by echocardiography and pathology.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In TO-2 hamsters, LV end-diastolic dimension was significantly smaller with GHRP‑6 than with GH.

    In plain wordsIn hamsters with cardiomyopathy, the heart's left ventricle was smaller after GHRP‑6 than after GH.

    Peptide
    GHRP-6
    Outcome
    DecreaseLV end-diastolic dimension versus GH
    Study

    hamstern: not reported in source

    TO-2 dilated cardiomyopathy
    Comparator
    GH
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    100 microg/kg day · injection · 4 weeksAs given in this study (hamster).

    Source sentences

    Summary
    The LVDd was significantly smaller in animals treated with GHRP-6 than in those treated with GH.
    2 context sentences
    Summary · context
    TO-2 hamsters (8 weeks old) were injected with GHRP-6 (100 microg/kg day), GH (2 mg/kg day), or saline for 4 weeks; F1B hamsters served as controls.
    Summary · context
    LV functional and structural changes were evaluated by echocardiography and pathology.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In TO-2 hamsters, GHRP‑6 did not increase LV myocyte cross-sectional area.

    In plain wordsIn hamsters with cardiomyopathy, GHRP‑6 did not increase heart muscle cell area compared with saline.

    Peptide
    GHRP-6
    Outcome
    No significant changeLV myocyte cross-sectional area
    Study

    hamstern: not reported in source

    TO-2 dilated cardiomyopathy
    Comparator
    Saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    100 microg/kg day · injection · 4 weeksAs given in this study (hamster).

    Source sentences

    Summary
    The cross-sectional LV myocyte area and the amount of atrial natriuretic peptide mRNA in the LV were increased by GH but not by GHRP-6.
    2 context sentences
    Summary · context
    TO-2 hamsters (8 weeks old) were injected with GHRP-6 (100 microg/kg day), GH (2 mg/kg day), or saline for 4 weeks; F1B hamsters served as controls.
    Summary · context
    LV functional and structural changes were evaluated by echocardiography and pathology.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In TO-2 hamsters, GHRP‑6 did not increase LV atrial natriuretic peptide mRNA.

    In plain wordsIn hamsters with cardiomyopathy, GHRP‑6 did not increase left ventricular atrial natriuretic peptide gene expression compared with saline.

    Peptide
    GHRP-6
    Outcome
    No significant changeLV atrial natriuretic peptide mRNA
    Study

    hamstern: not reported in source

    TO-2 dilated cardiomyopathy
    Comparator
    Saline
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    100 microg/kg day · injection · 4 weeksAs given in this study (hamster).

    Source sentences

    Summary
    The cross-sectional LV myocyte area and the amount of atrial natriuretic peptide mRNA in the LV were increased by GH but not by GHRP-6.
    2 context sentences
    Summary · context
    TO-2 hamsters (8 weeks old) were injected with GHRP-6 (100 microg/kg day), GH (2 mg/kg day), or saline for 4 weeks; F1B hamsters served as controls.
    Summary · context
    LV functional and structural changes were evaluated by echocardiography and pathology.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.